|
WO2006013370A1
|
|
Pharmaceutical composition containing botulinum neurotoxin a2
|
|
GB0424048D0
|
|
Treatment of cardiac fibrillation disorders
|
|
GB0423953D0
|
|
Pharmaceutical composition containing botulinum neurotoxin
|
|
GB0423952D0
|
|
Pharmaceutical composition containing botulinum neurotoxin
|
|
GB0423950D0
|
|
Pharmaceutical composition comprising botulinum neurotoxin
|
|
GB0421288D0
|
|
Pharmaceutical composition comprising botulinum neurotoxin
|
|
GB0421290D0
|
|
Pharmaceutical composition comprising botulinum neurotoxin
|
|
GB0417366D0
|
|
Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample
|
|
GB0417367D0
|
|
Pharmaceutical composition containing botulinum neurotoxin
|
|
GB0415490D0
|
|
Therapeutic use of Botulinum toxin
|
|
GB0415491D0
|
|
Botulinum neurotoxin composition
|
|
KR20060000043A
|
|
Pharmaceutical composition comprising botulinum toxin for treating knee joint pain by saphenous nerve entrapment
|
|
GB0303997D0
|
|
Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
|
